Trial Profile
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria: An Open-label, Single-arm, Exploratory Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 18 Dec 2023 Planned End Date changed from 1 Oct 2023 to 1 May 2024.
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2022 Planned number of patients changed from 20 to 24.